| Sumario: | Significance & Background: In January 2023, our National Cancer Institute-designated comprehensive cancer center launched a weekly multidisciplinary clinic, the Genetic Cancer Prevention Clinic (GCPC), for individuals at an increased risk for hereditary cancer due to a known pathogenic variant (PV). As part of the multidisciplinary team, the genetic nurse navigator (GNN) provides education about hereditary cancers and assists with coordination of high-risk surveillance and/or prophylactic procedures, as well as support for cascade testing of family members. Purpose: The GCPC mission is to reduce cancer incidence through coordination and implementation of longitudinal cancer risk reduction efforts, promotion of cascade testing, and research. Data was collected through retrospective chart review; this was determined to be non-regulated research through our Institutional Re-view Board. Interventions: Patients are seen annually by a genetic counselor, advanced practice provider or physician, and GNN. Before the appointment, the GNN reviews the chart and calls the patient to confirm genetic test results, update personal/ family history, and adherence to recommended risk-management interventions. Each case, along with pertinent updates and plans, is discussed in a multidisciplinary conference prior to clinic. National Comprehensive Cancer Network guidelines and recommended screenings are shared with the patient at the time of their visit and each of the patient's relevant providers through the visit note. Results: Between January 2023 and June 2025, there were 704 unique patient encounters (new and/ or established patients) in GCPC. Patients had PV's in 39 different genes, most commonly (56% of all PVs) in the ATM, BRCA1, BRCA2, CHEK2, and PALB2 genes. Sixty-two percent of patients were previvors; 98% reported family history of cancer; 79% were female; 61% were age 50 or younger; and 98% were English-speaking. Patients residing in 43 counties were served across 4 states. Sixty-two underwent updated genetic testing as a result of their GCPC visit; 13% had a newly identified PV. There were 807 referrals placed, and 4,135 pieces of educational materials provided. Discussion: Patient volumes have continued to grow in our third year. In addition to a steady flow of new patients, we are now seeing established patients, and we have greatly expanded our GCPC clinic schedule. Most current data will be included if invited to share in a poster. The GNN has played an integral role within the multidisciplinary team in the development and ongoing adjustments to GCPC.
|
|---|